Table 4.
Summary of the Patient with the Three Lenvatinib-induced Interstitial Pneumonia Reported in the Literature.
| Case of Study [referene] |
Age | Sex | Cancer type | PS | Smoking history (pack year) | Complication of interstitial pneumonia before the start of lenvatinib | Time from first administration to the onset of drug-induced interstitial pneumonitis (month) | Pattern of HRCT | KL-6 (U/mL) |
Lymphocyte ration of BAL(%) | TBLB | DLST | treatment | outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case Rep Oncol 11:75-80, 2018 [7]. |
67 | M | Cncer of unknown primary (Squamous cell carcinoma) | 0 | 15 | no complication | 1 | bilateral GGO | 582 | 61.10% | no data | positive | discontinuation of lenvatinib | recoverd |
| Clin J Gastroenterol 12: 355-360, 2019 [8]. |
59 | M | HCC | 0 | 45 | complication of mild interstitial pneumonitis induced by regorafenib | 1 | bilateral GGO | 1283 | no data | no data | negative | discontinuation of lenvatinib steroid therapy | recoverd |
| present case | 84 | M | HCC | 1 | 24 | no complication | 4 | bilateral GGO ⇒bilateral infiltration shadow |
1906 | 20.80% | infiltration of lymphocyte into alveolar interstitium | positive | discontinuation of lenvatinib steroid therapy | recoverd |
BAL: bronchoalveolar lavage, DLST: drug induced lymphocyte stimulation test, GGO: ground-glass opacity, HCC: hepatic cell carcinoma, HRCT: high-resolution chest tomography, KL-6: Krebs von den Lugen-6, PS: performance status, TBLB: transbronchial lung biopsy